amsacrine has been researched along with Leukemia, Myeloid in 54 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 7.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 3.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| " Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease." | 2.72 | Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. ( de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006) |
| "At ABMT, 17 patients were in untreated relapse and one was in third complete remission (CR)." | 2.68 | Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. ( Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA, 1996) |
| " The patients were randomised at diagnosis to receive either three further courses of Ara-C (five days) and DNR (two days) in the same dosage or three courses of VP16 100 mg/m2 daily for five days and one dose of mAMSA of 200 mg/m2 as postremission consolidation." | 2.67 | Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology. ( , 1991) |
| "HDARAC is also active in acute lymphocytic leukemia." | 2.37 | High dose cytarabine: a review. ( Bolwell, BJ; Cassileth, PA; Gale, RP, 1988) |
| " The pharmacokinetic data served as a guideline for in vitro toxicity tests on clonogenic bone marrow cells." | 1.29 | Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ( Brons, P; de Witte, T; Knops, G; Linssen, P; Wessels, H, 1993) |
| " A single dose of CY or four consecutive daily doses of AMSA produced increased survival in leukemic rats, with a positive-slope dose-response curve up to the maximum tolerated dose (MTD)." | 1.28 | Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model. ( Cordel, K; Holm, C; Vaughan, WP, 1989) |
| "Amsacrine is an active antileukemic agent known to induce cardiac arrhythmias, although the incidence of these cardiac events is low." | 1.27 | Amsacrine is safe in patients with ventricular ectopy. ( Arlin, ZA; Feldman, EJ; Puccio, CA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (18.52) | 18.7374 |
| 1990's | 28 (51.85) | 18.2507 |
| 2000's | 16 (29.63) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Vliet, MJ | 1 |
| Tissing, WJ | 1 |
| Rings, EH | 1 |
| Koetse, HA | 1 |
| Stellaard, F | 1 |
| Kamps, WA | 1 |
| de Bont, ES | 1 |
| Tavernier, E | 1 |
| Le, QH | 2 |
| Elhamri, M | 2 |
| Thomas, X | 3 |
| Kell, WJ | 1 |
| Burnett, AK | 1 |
| Chopra, R | 1 |
| Yin, JA | 1 |
| Clark, RE | 1 |
| Rohatiner, A | 1 |
| Culligan, D | 1 |
| Hunter, A | 1 |
| Prentice, AG | 1 |
| Milligan, DW | 1 |
| Höglund, M | 1 |
| Brune, M | 1 |
| Sallerfors, B | 1 |
| Ahlgren, T | 1 |
| Billström, R | 1 |
| Hedenus, M | 2 |
| Markevärn, B | 1 |
| Nilsson, B | 1 |
| Simonsson, B | 2 |
| Stockelberg, D | 1 |
| Wahlin, A | 2 |
| Fouillard, L | 2 |
| Labopin, M | 1 |
| Meloni, G | 2 |
| Polge, E | 1 |
| Gorin, NC | 2 |
| Frassoni, F | 1 |
| Perel, Y | 2 |
| Auvrignon, A | 1 |
| Leblanc, T | 2 |
| Michel, G | 2 |
| Vannier, JP | 2 |
| Dalle, JH | 1 |
| Gandemer, V | 1 |
| Schmitt, C | 1 |
| Mèchinaud, F | 1 |
| Lamagnere, JP | 1 |
| Piguet, Ch | 1 |
| Couillaud, G | 1 |
| Pautard, B | 1 |
| Baruchel, A | 2 |
| Leverger, G | 2 |
| Hofmann, WK | 1 |
| Heil, G | 1 |
| Zander, C | 1 |
| Wiebe, S | 1 |
| Ottmann, OG | 1 |
| Bergmann, L | 1 |
| Hoeffken, K | 1 |
| Fischer, JT | 1 |
| Knuth, A | 1 |
| Kolbe, K | 1 |
| Schmoll, HJ | 1 |
| Langer, W | 1 |
| Westerhausen, M | 1 |
| Koelbel, CB | 1 |
| Hoelzer, D | 1 |
| Ganser, A | 1 |
| Kalaycio, M | 1 |
| Rao, A | 1 |
| Hills, RK | 1 |
| Stiller, C | 1 |
| Gibson, BE | 1 |
| de Graaf, SS | 1 |
| Hann, IM | 2 |
| O'Marcaigh, A | 1 |
| Wheatley, K | 2 |
| Webb, DK | 1 |
| Tan, RM | 1 |
| Quah, TC | 1 |
| Aung, L | 1 |
| Liang, S | 1 |
| Kirk, RC | 1 |
| Yeoh, AE | 1 |
| Raffoux, E | 1 |
| Botton, Sd | 1 |
| Pautas, C | 1 |
| Arnaud, P | 1 |
| de Revel, T | 1 |
| Reman, O | 1 |
| Terré, C | 1 |
| Corront, B | 1 |
| Gardin, C | 1 |
| Quesnel, B | 1 |
| Cordonnier, C | 1 |
| Bourhis, JH | 1 |
| Fenaux, P | 1 |
| Preudhomme, C | 1 |
| Michallet, M | 1 |
| Castaigne, S | 1 |
| Dombret, H | 1 |
| Suciu, S | 1 |
| Rio, B | 1 |
| Leone, G | 1 |
| Broccia, G | 1 |
| Fillet, G | 1 |
| Jehn, U | 2 |
| Feremans, W | 1 |
| Vignetti, M | 1 |
| de Witte, T | 3 |
| Amadori, S | 1 |
| Miller, LP | 1 |
| Miller, DR | 1 |
| Tan, CT | 1 |
| Omura, GA | 1 |
| Winton, EF | 1 |
| Vogler, WR | 1 |
| Zuckerman, KS | 1 |
| Grillo-Lopez, AJ | 1 |
| Case, DC | 1 |
| Spiro, TE | 1 |
| Socquet, M | 1 |
| Delforge, A | 1 |
| Stryckmans, P | 1 |
| Legha, SS | 1 |
| Keating, MJ | 2 |
| McCredie, KB | 2 |
| Bodey, GP | 1 |
| Freireich, EJ | 2 |
| Momparler, RL | 1 |
| Doré, BT | 1 |
| Labiberté, J | 1 |
| Momparler, LF | 1 |
| Willemze, R | 1 |
| Archimbaud, E | 1 |
| Muus, P | 1 |
| Watson, AM | 1 |
| Seymour, J | 1 |
| Lee, N | 1 |
| Whiteside, M | 1 |
| Firkin, F | 1 |
| Poddubnaia, IV | 1 |
| Perilov, AA | 1 |
| Linssen, P | 1 |
| Brons, P | 1 |
| Knops, G | 1 |
| Wessels, H | 1 |
| Nelken, B | 1 |
| Landman-Parker, J | 1 |
| Thuret, I | 1 |
| Bergeron, C | 1 |
| Bordigoni, P | 1 |
| Esperou-Bourdeau, H | 1 |
| Schaison, G | 1 |
| Klumper, E | 1 |
| Ossenkoppele, GJ | 1 |
| Pieters, R | 1 |
| Huismans, DR | 1 |
| Loonen, AH | 1 |
| Rottier, A | 1 |
| Westra, G | 1 |
| Veerman, AJ | 1 |
| Ghaddar, HM | 1 |
| Pierce, S | 1 |
| Kantarjian, HM | 1 |
| Estey, EH | 1 |
| de la Rubia, J | 1 |
| Sanz, GF | 1 |
| Martín, G | 1 |
| Sempere, A | 1 |
| Picón, I | 1 |
| Carral, A | 1 |
| Larrea, L | 1 |
| Martínez, J | 1 |
| Soler, MA | 1 |
| Bonanad, S | 1 |
| López, F | 1 |
| Jarque, I | 1 |
| Sanz, MA | 1 |
| de Nully Brown, P | 1 |
| Hoffmann, T | 1 |
| Hansen, OP | 1 |
| Boesen, AM | 1 |
| Grønbaek, K | 1 |
| Hippe, E | 1 |
| Jensen, MK | 1 |
| Thorling, K | 1 |
| Storm, HH | 1 |
| Pedersen-Bjergaard, J | 1 |
| Brinch, L | 1 |
| Hörnsten, P | 1 |
| Evensen, SA | 1 |
| Oberg, G | 1 |
| Stevens, RF | 1 |
| Gray, RG | 1 |
| Gore, SD | 1 |
| Burke, PJ | 2 |
| Weng, LJ | 1 |
| Ozkaynak, MF | 1 |
| Avramis, VI | 1 |
| Carcich, S | 1 |
| Ortega, JA | 1 |
| Navarro, JT | 1 |
| Hernández, JA | 1 |
| Ribera, JM | 1 |
| Sancho, JM | 1 |
| Oriol, A | 1 |
| Pujol, M | 1 |
| Millá, F | 1 |
| Feliu, E | 1 |
| Harousseau, JL | 3 |
| Witz, B | 1 |
| Lioure, B | 1 |
| Hunault-Berger, M | 1 |
| Desablens, B | 3 |
| Delain, M | 1 |
| Guilhot, F | 1 |
| Le Prise, PY | 1 |
| Abgrall, JF | 1 |
| Deconinck, E | 1 |
| Guyotat, D | 1 |
| Vilque, JP | 1 |
| Casassus, P | 3 |
| Tournilhac, O | 1 |
| Audhuy, B | 1 |
| Solary, E | 1 |
| Nørgaard, JM | 2 |
| Langkjer, ST | 1 |
| Palshof, T | 1 |
| Pedersen, B | 2 |
| Hokland, P | 2 |
| Isnard, F | 1 |
| Guiguet, M | 1 |
| Laporte, JP | 1 |
| Zunic, P | 1 |
| Elloumi, M | 1 |
| Chéron, N | 1 |
| Deloux, J | 1 |
| Van Den Akker, J | 1 |
| Lesage, S | 1 |
| Aoudjhane, M | 1 |
| Lopez, M | 1 |
| Douay, L | 1 |
| Najman, A | 1 |
| Olesen, LH | 1 |
| Olesen, G | 1 |
| Meyer, K | 1 |
| Kristensen, JS | 1 |
| Bendix, K | 1 |
| Kjeldsen, E | 1 |
| Kettle, AJ | 1 |
| Robertson, IG | 1 |
| Palmer, BD | 1 |
| Anderson, RF | 1 |
| Patel, KB | 1 |
| Winterbourn, CC | 1 |
| Larson, RA | 1 |
| Day, RS | 1 |
| Azarnia, N | 1 |
| Bennett, JM | 2 |
| Browman, G | 1 |
| Goldberg, J | 1 |
| Gottlieb, A | 1 |
| Grunwald, H | 1 |
| Miller, K | 1 |
| Raza, A | 1 |
| Cassileth, PA | 2 |
| Lynch, E | 1 |
| Hines, JD | 1 |
| Oken, MM | 1 |
| Mazza, JJ | 1 |
| McGlave, PB | 1 |
| Edelstein, M | 1 |
| Harrington, DP | 1 |
| O'Connell, MJ | 1 |
| Zittoun, R | 2 |
| Liso, V | 1 |
| Mandelli, F | 1 |
| Rotoli, B | 1 |
| Gattringer, C | 1 |
| Resegotti, L | 1 |
| Caronia, F | 1 |
| Leoni, P | 1 |
| Petti, MC | 1 |
| Horn, TD | 1 |
| Kerker, BJ | 1 |
| Karp, JE | 1 |
| Hood, AF | 1 |
| Milpied, N | 2 |
| Briere, J | 2 |
| Leprise, PY | 2 |
| Ifrah, N | 2 |
| Gandhour, B | 2 |
| Freund, M | 1 |
| Giller, S | 1 |
| Hinrichs, F | 1 |
| Baars, A | 1 |
| Meran, J | 1 |
| Körfer, A | 1 |
| Link, H | 1 |
| Poliwoda, H | 1 |
| Zwelling, LA | 2 |
| Mayes, J | 2 |
| Deisseroth, K | 1 |
| Hinds, M | 2 |
| Grant, G | 1 |
| Pathak, S | 1 |
| Ledley, FD | 1 |
| Vyas, R | 1 |
| Hittelman, W | 1 |
| Del Bino, G | 1 |
| Darzynkiewicz, Z | 1 |
| Chan, D | 1 |
| Altschuler, E | 1 |
| Zipf, TF | 1 |
| Puccio, CA | 1 |
| Feldman, EJ | 1 |
| Arlin, ZA | 1 |
| Vaughan, WP | 1 |
| Holm, C | 1 |
| Cordel, K | 1 |
| Bolwell, BJ | 1 |
| Gale, RP | 1 |
| Andersson, BS | 1 |
| Beran, M | 1 |
| Barlogie, B | 1 |
| Van, NT | 1 |
| Marie, JP | 1 |
| Zittoun, J | 1 |
| Marquet, J | 1 |
| Haanen, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ACUTE MYELOID LEUKAEMIA TRIAL 12[NCT00002658] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1994-01-31 | Active, not recruiting | ||
| Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML[NCT00880243] | Phase 3 | 473 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)[NCT00002719] | Phase 3 | 500 participants (Anticipated) | Interventional | 1995-12-31 | Completed | ||
| Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2[NCT00149162] | Phase 3 | 580 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amsacrine and Leukemia, Myeloid
| Article | Year |
|---|---|
High dose cytarabine: a review.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; H | 1988 |
24 trials available for amsacrine and Leukemia, Myeloid
| Article | Year |
|---|---|
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ca | 2009 |
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aminoglycosides; Amsacrine; Antibodies, Monoclonal; A | 2003 |
More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Co | 2003 |
Maintenance therapy in childhood acute myeloid leukemia.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow | 2004 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Com | 2004 |
Induction chemotherapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunoru | 2005 |
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyta | 2006 |
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Di | 2007 |
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Proto | 2007 |
Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bon | 1994 |
Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation | 1996 |
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Co | 1996 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined | 1997 |
Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Proto | 1997 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 1998 |
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; | 2000 |
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemot | 1992 |
Varying intensity of postremission therapy in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 1992 |
Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherap | 1992 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmust | 1991 |
Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; D | 1991 |
Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Analysis of Variance; Antibiotics, Antineoplastic | 1991 |
29 other studies available for amsacrine and Leukemia, Myeloid
| Article | Year |
|---|---|
Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmus | 2004 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and | 2007 |
Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Topics: Adolescent; Aminoacridines; Amsacrine; Ancitabine; Antineoplastic Agents; Child; Child, Preschool; C | 1983 |
Phase II study of amsacrine gluconate in refractory leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Gluconates; Humans; Lactates; Leuke | 1983 |
m-AMSA: phase II trial in advanced lymphoma and leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marro | 1984 |
Chemotherapeutic sensitivity of normal and leukemic hematopoietic progenitor cells to N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulfonamide, a new anticancer agent.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow; Colony-Forming Units Assay; Hematopoi | 1981 |
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; H | 1982 |
Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
Topics: Amsacrine; Antineoplastic Agents; Azacitidine; Calcitriol; Decitabine; Drug Interactions; Drug Scree | 1993 |
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; F | 1993 |
An effective age-unrestricted m-AMSA-based second-line regimen for poor prognosis acute myeloid leukaemia.
Topics: Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; | 1994 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytara | 1993 |
Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L).
Topics: Acute Disease; Adult; Amsacrine; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Division; Cell S | 1993 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine | 1996 |
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; D | 1998 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Co | 2001 |
Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2001 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplas | 2001 |
Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase.
Topics: Amsacrine; Humans; Hypochlorous Acid; Leukemia, Myeloid; Neutrophils; Oxidation-Reduction; Peroxidas | 1992 |
Endothelial expression of intercellular adhesion molecule (ICAM-1) is unaffected by marrow aplasia-inducing chemotherapy.
Topics: Amsacrine; Antigens, CD; Antineoplastic Agents; Bone Marrow; Cell Adhesion Molecules; Cytarabine; Da | 1991 |
A restriction fragment length polymorphism for human topoisomerase II: possible relationship to drug-resistance.
Topics: Alleles; Amsacrine; Chromosomes, Human, Pair 17; DNA; DNA Topoisomerases, Type II; Drug Resistance; | 1990 |
Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
Topics: Amsacrine; Camptothecin; Cell Line; DNA; Doxorubicin; Humans; In Vitro Techniques; Leukemia, Myeloid | 1991 |
Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
Topics: Amsacrine; Cell Adhesion; Cell Differentiation; Cell Survival; DNA Damage; DNA Topoisomerases, Type | 1990 |
Amsacrine is safe in patients with ventricular ectopy.
Topics: Aged; Amsacrine; Cardiac Complexes, Premature; Cytarabine; Drug Therapy, Combination; Electrocardiog | 1988 |
Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
Topics: Amsacrine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response | 1989 |
Analysis of nuclear m-AMSA content by DNA fluorochrome competition.
Topics: Amsacrine; Antineoplastic Agents; Carbon Radioisotopes; Cell Line; Cell Nucleus; Flow Cytometry; Hum | 1986 |
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistan | 1985 |